Rac1b: An emerging therapeutic target for chemoresistance in colorectal cancer

Abstract 5-Flurouracil (5-FU) and oxaliplatin (OXA) are standard chemotherapy for advanced stage and metastatic colorectal cancer (CRC). Although initial responses to chemotherapy may be successful, the development of chemoresistance for most patients is inevitable. Therefore better understanding of the underlying mechanisms that drive chemotherapy resistance will guide better treatment strategies to hopefully improve patient outcomes. Rac1b, a constitutively active alternative splice variant of Rac1, has been implicated in the growth and survival, and is believed to be associated with CRC progression and metastasis. Rac1b has also been shown to play a significant role in resistance to cytotoxic chemotherapeutics largely in part by activation of pro-survival NF-κB signaling. High Rac1b levels present a novel biomarker of disease progression and chemoresistance as well as present a novel therapeutic target for CRC.

• Publication year

  2020

• Venue

  Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/b978-0-12-819937-4.00009-1
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotherapy in colorectal cancer: rationale, challenges and potential

  2019cited by this paper
• RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer

  2019cited by this paper
• Drug resistance and new therapies in colorectal cancer

  2018cited by this paper
• Crosstalk between Rac1-mediated actin regulation and ROS production.

  2018cited by this paper
• NF-κB, inflammation, immunity and cancer: coming of age

  2018cited by this paper
• Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors

  2018cited by this paper
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2018cited by this paper
• RAC1-GTP promotes epithelial-mesenchymal transition and invasion of colorectal cancer by activation of STAT3

  2018cited by this paper
• The Rac1 splice form Rac1b favors mouse colonic mucosa regeneration and contributes to intestinal cancer progression

  2018cited by this paper
• Epithelial Mesenchymal Transition in Tumor Metastasis.

  2018cited by this paper
• Loss of neural crest‐associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulation

  2018cited by this paper
• Negative regulation of TGF-β1-induced MKK6-p38 and MEK-ERK signalling and epithelial-mesenchymal transition by Rac1b

  2017cited by this paper
• Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer

  2017cited by this paper
• The Rac GTPase in Cancer: From Old Concepts to New Paradigms.

  2017cited by this paper
• RAC1b overexpression stimulates proliferation and NF-kB-mediated anti-apoptotic signaling in thyroid cancer cells

  2017cited by this paper
• High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine

  2016cited by this paper
• Deregulation of Rho GTPases in cancer

  2016cited by this paper
• Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms

  2016cited by this paper
• The biology and function of fibroblasts in cancer

  2016cited by this paper
• Rac1b enhances cell survival through activation of the JNK2/c-JUN/Cyclin-D1 and AKT2/MCL1 pathways

  2016cited by this paper
• Pharmacologic resistance in colorectal cancer: a review

  2016cited by this paper
• Critical off‐target effects of the widely used Rac1 inhibitors NSC23766 and EHT1864 in mouse platelets

  2015cited by this paper
• TCGASpliceSeq a compendium of alternative mRNA splicing in cancer

  2015cited by this paper
• Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression

  2015cited by this paper
• Expression of tumor-related Rac1b antagonizes B-Raf-induced senescence in colorectal cells.

  2015cited by this paper
• Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease

  2014cited by this paper
• Colorectal cancer statistics, 2014

  2014cited by this paper
• RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.

  2014cited by this paper
• Matrix Metalloproteinase (MMP)-9 in Cancer-Associated Fibroblasts (CAFs) Is Suppressed by Omega-3 Polyunsaturated Fatty Acids In Vitro and In Vivo

  2014cited by this paper
• Ibuprofen inhibits colitis-induced overexpression of tumor-related Rac1b.

  2013cited by this paper
• Cancer Genome Landscapes

  2013cited by this paper
• RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis

  2013cited by this paper
• ROS Production and NF-κB Activation Triggered by RAC1 Facilitate WNT-Driven Intestinal Stem Cell Proliferation and Colorectal Cancer Initiation

  2013cited by this paper
• Matrix compliance regulates Rac1b localization, NADPH oxidase assembly, and epithelial–mesenchymal transition

  2012cited by this paper
• Characterization of EHop-016, Novel Small Molecule Inhibitor of Rac GTPase*

  2012cited by this paper
• Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance

  2012cited by this paper
• PAK signaling in cancer

  2012cited by this paper
• The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis

  2012cited by this paper
• Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

  2012cited by this paper
• The E3 ubiquitin-ligase HACE1 catalyzes the ubiquitylation of active Rac1.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Cancer Associated Fibroblasts Exploit Reactive Oxygen Species Through a Proinflammatory Signature Leading to Epithelial Mesenchymal Transition and Stemness

  2011cited by this paper
• The 19-Amino Acid Insertion in the Tumor-associated Splice Isoform Rac1b Confers Specific Binding to p120 Catenin*

  2010cited by this paper
• Effects of 5-FU.

  2010cited by this paper
• Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

  2010cited by this paper
• Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer

  2010cited by this paper
• Rac GTPases in Human Diseases

  2010cited by this paper
• Sequencing technologies — the next generation

  2010cited by this paper
• Is NF-κB a good target for cancer therapy? Hopes and pitfalls

  2009cited by this paper
• APC and its modifiers in colon cancer.

  2009cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Structure-activity relationship of isoform selective inhibitors of Rac1/1b GTPase nucleotide binding.

  2009cited by this paper
• Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors.

  2009cited by this paper
• NF-κB Signaling Pathway, Inflammation and Colorectal Cancer

  2009cited by this paper
• Increased Rac1b Expression Sustains Colorectal Tumor Cell Survival

  2008cited by this paper
• DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice.

  2008cited by this paper
• Nuclear factor-?B1: Regulation and function

  2008cited by this paper
• Alkylating agents induce activation of NFκB in multiple myeloma cells

  2008cited by this paper
• B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival.

  2008cited by this paper
• Activation of tumor-specific splice variant Rac1b by dishevelled promotes canonical Wnt signaling and decreased adhesion of colorectal cancer cells.

  2007cited by this paper
• Role of IKK and oscillatory NFκB kinetics in MMP‐9 gene expression and chemoresistance to 5‐fluorouracil in RKO colorectal cancer cells

  2007cited by this paper
• The resurgence of platinum-based cancer chemotherapy

  2007cited by this paper
• Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases*

  2007cited by this paper
• Association between DNA Methylation and Shortened Survival in Patients with Advanced Colorectal Cancer Treated with 5-Fluorouracil–Based Chemotherapy

  2007cited by this paper
• Cell type-specific functions of Rho GTPases revealed by gene targeting in mice.

  2007cited by this paper
• Cetuximab for the treatment of colorectal cancer.

  2007cited by this paper
• Current status of excision repair cross complementing-group 1 (ERCC1) in cancer.

  2007cited by this paper
• Rho GTPases: promising cellular targets for novel anticancer drugs.

  2006cited by this paper
• Rac1, but Not Rac1B, Stimulates RelB-mediated Gene Transcription in Colorectal Cancer Cells*

  2006cited by this paper
• Purification and biochemical properties of Rac1, 2, 3 and the splice variant Rac1b.

  2006cited by this paper
• Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability

  2005cited by this paper
• (Neo-)adjuvant treatments in colorectal cancer.

  2005cited by this paper
• Expression of Rac1b stimulates NF-kappaB-mediated cell survival and G1/S progression.

  2005cited by this paper
• IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy

  2005cited by this paper
• RAC1 Inhibition Targets Amyloid Precursor Protein Processing by γ-Secretase and Decreases Aβ Production in Vitro and in Vivo*

  2005cited by this paper
• Nuclear factor-κB inhibitors as sensitizers to anticancer drugs

  2005cited by this paper
• Advances in protein kinase B signalling: AKTion on multiple fronts.

  2004cited by this paper
• Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation

  2004cited by this paper
• XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

  2004cited by this paper
• Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

  2004cited by this paper
• IKK Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer

  2004cited by this paper
• Alternative Splicing of Rac1 Generates Rac1b, a Self-activating GTPase*

  2004cited by this paper
• Rational design and characterization of a Rac GTPase-specific small molecule inhibitor.

  2004cited by this paper
• Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models*

  2004cited by this paper
• Mechanistic and Predictive Profiling of 5-Fluorouracil Resistance in Human Cancer Cells

  2004cited by this paper
• Inducible nuclear factor-κB activation contributes to chemotherapy resistance in gastric cancer1 ☆

  2004cited by this paper
• Tumor-related Alternatively Spliced Rac1b Is Not Regulated by Rho-GDP Dissociation Inhibitors and Exhibits Selective Downstream Signaling*

  2003cited by this paper
• Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line.

  2003cited by this paper
• Disulfiram‐mediated inhibition of NF‐κB activity enhances cytotoxicity of 5‐fluorouracil in human colorectal cancer cell lines

  2003cited by this paper
• To be, or not to be: NF-κB is the answer – role of Rel/NF-κB in the regulation of apoptosis

  2003cited by this paper
• Rho protein inactivation induced apoptosis of cultured human endothelial cells.

  2002cited by this paper
• Inflammation and cancer

  2002cited by this paper
• Mechanisms of resistance to cisplatin.

  2001cited by this paper
• Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b

  2000cited by this paper
• Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.

  2000cited by this paper
• Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

  2000cited by this paper
• Efficacy of oxaliplatin in the treatment of colorectal cancer.

  2000cited by this paper
• Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB

  1999cited by this paper

• RNPS1 functions as an oncogenic splicing factor in cervical cancer cells

  2022cites this paper
• Differentially Expressed Cell Cycle Genes and STAT1/3-Driven Multiple Cancer Entanglement in Psoriasis, Coupled with Other Comorbidities

  2022cites this paper